Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.

Caitriona Cahir Xin Victoria Wang David M Hyman Petros D Grivas Edith P Mitchell John J Wright Elad Sharon Robert C Gray Lisa Meier McShane Lawrence V Rubinstein David R Patton P Mickey Williams Stanley R Hamilton Jue Wang Kari B Wisinski James V Tricoli Barbara A Conley Lyndsay N Harris Carlos L Arteaga Peter J O'Dwyer Helen X Chen Keith T Flaherty

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

HP was active in a selection of HER2-amplified tumors (non-breast/gastroesophageal) but did not meet the predefined efficacy benchmark. Additional strategies targeting HER2 and potential resistance pathways are warranted, especially in rare tumors.

Keyphrases

epidermal growth factor receptor
clinical trial
metastatic breast cancer
study protocol
randomized controlled trial
cancer therapy
phase iii
phase ii
risk assessment
drug delivery
climate change
tyrosine kinase